Manufacturer
SM PHARMACEUTICALS SDN. BHD.
Contents
Lignocaine HCl
Indication
Local anaesth, dental infiltration or nerve block, local infiltration, peripheral nerve block, sympathetic block & transtracheal anaesth.
Instruction
Adult Infiltration Percutaneous: 5-300 mg. Peripheral nerve block Brachial: 225-300 mg. Intercostal: 30 mg. Paracervical: 100 mg/side as 1% soln, may be repeated at intervals of not <90 min. Paravertebral: 30-50 mg. Retrobulbar: 120-200 mg. Sympathetic nerve block Cervical: 50 mg. Transtracheal: 80-120 mg & additional 4% spray to pharynx may be required. Max: Not to exceed 4.5 mg/kg. Childn Local infiltration Up to 4.5 mg/kg as 0.25-5% soln. Nerve block Up to 4.5 mg/kg as 0.5-1% soln.
Drug interaction
Antagonise effects of antimyasthenics on skeletal muscle. Additive depressant effect w/ CNS depressants. Release heavy metal ions from disinfectant soln which may cause severe local irritation, swelling & oedema. Excessive circulation restriction w/ methoxamine. Ischaemia leading to gangrene may result w/ other vasoconstrictors eg, adrenaline or phenylephrine. Increased risk of lignocaine toxicity (reduced metabolism) w/ β-adrenergic blocking agents. Inhibition of hepatic metabolism w/ cimetidine.
Malaysia
